Cerevast Medical, Inc. is focused on advancing healthcare through innovative technologies, particularly in the realm of ultrasound applications for medical treatment. The company has a robust pipeline that includes clinical stage programs utilizing transcranial ultrasound combined with tissue plasminogen activator for treating ischemic stroke, as well as ophthalmic ultrasound with microspheres for addressing retinal vein occlusions. Additionally, Cerevast is exploring development stage programs that leverage transcranial ultrasound for neuromodulation and enhanced drug delivery, showcasing a commitment to improving patient care across various medical conditions.

One of the key technologies being developed by Cerevast is transcranial ultrasound neuromodulation, which allows for non-invasive stimulation of the brain. This technique alters nerve activity by delivering ultrasound waves to specific neurological sites, offering advantages over traditional methods like deep brain stimulation and transcranial magnetic stimulation. The ability of ultrasound to penetrate deeper into the brain with high spatial resolution positions it as a promising tool for promoting recovery and rehabilitation in stroke patients. Cerevast's upcoming commercial device aims to enhance neuroplastic repair mechanisms in the brain, providing healthcare professionals with an effective therapeutic option directly at the point-of-care.

United States

Founded in 2015, Cerevast Medical, Inc. is a clinical-stage medical device company based in Bothell, Washington, USA.

Leveraging our core expertise in the fields of ultrasound and microsphere technologies, we are committed to developing novel, first-in-class therapeutic solutions to restore health and improve the quality of life for patients that suffer from major diseases.

Cerevast Medical, Inc.

Company Details